Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Schrodinger Inc (NQ: SDGR )

23.26 -0.46 (-1.94%)
Streaming Delayed Price Updated: 2:50 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Schrodinger Inc

< Previous 1 2 3 4 Next >
Schrödinger to Announce Second Quarter 2023 Financial Results on August 2
From Schrödinger, Inc.
Via Business Wire
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger to Present at Jefferies Global Biopharma Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Reports Strong First Quarter 2023 Financial Results
From Schrödinger, Inc.
Via Business Wire
Schrödinger Publishes Inaugural Corporate Sustainability Report
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Announce First Quarter 2023 Financial Results on May 4
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
MarketBeat Week in Review – 3/6 - 3/10
Stocks are down sharply to end the week, and the MarketBeat staff continues to show investors why dividend stocks need to be part of your playbook 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
From Schrödinger Inc.
Via Business Wire
Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28
From Schrödinger
Via Business Wire
Schrödinger to Present at SVB Securities Global Biopharma Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities
From Schrödinger, Inc.
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting
From Schrödinger
Via Business Wire
Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Third Quarter 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Announce Third Quarter 2022 Financial Results on November 3
From Schrödinger
Via Business Wire
Schrödinger Hosts Platform Day
From Schrödinger
Via Business Wire
Schrödinger to Host Platform Day on October 6, 2022
From Schrödinger, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.